Ora Biomedical, Inc.

The Alliance for Longevity Initiatives applauds today’s relaunch of the Congressional Caucus for Longevity Science, a bipartisan effort that signals growing momentum for policies that prioritize aging and longevity research. Led by Representatives @RepGusBilirakis (R-FL), @RepPaulTonko (D-NY), @DanCrenshawTX (R-TX), @RepRoKhanna (D-CA), @RepScottPeters (D-CA) and @RepLiccardo (D-CA), the Caucus brings longevity science to the forefront of national policy conversations and reflects a clear commitment from Congress to extend not just lifespan, but healthspan. You can read the full announcement from Rep. Bilirakis' office here: bit.ly/4jPaWwE A4LI looks forward to working alongside the Caucus to drive policies that support innovation, promote equitable access to next-generation therapies, and advance a future where everyone can live better for longer.

Exciting news! $50 000 is now secured, which means that the first subproject is fully funded around the largest mTOR screening project that has ever been done! So @OraBiomedical can now begin the wormbot screening of the first 301 mTOR inhibitors out of the 601 in the full compound library. Why is this research project so exciting? Because one of the most promising compounds tested to date is the mTOR inhibitor Rapamycin. Notably, it's the only compound that has consistently demonstrated significant longevity effects across multiple species, including yeast, worms, flies and mice. Even partial genetic inhibition of mTOR has shown similar effects. The efficiency and reliability of reproducing healthy lifespan extension across multiple species has led to that partial mTOR inhibition is viewed as the gold standard in the field. So the goal with this research project is to take the first step to see if we can discover even more potent and better mTOR inhibitors than Rapamycin. A massive thanks to you to all who have made this milestone possible. In approximately three months from now we will start to see unique and important data delivered to the longevity field. This basic data will be publicly available for everyone. The goal of sharing this data is to facilitate research to progress from basic single compound studies to much more advanced and impactful longevity research. For example, my lab initiative Rapamycin Longevity Lab aims to develop advanced combinational longevity therapies with an mTOR inhibitor as the base. With the help of AI and by getting the basic data in place I’m confident we will start taking things to the next level. If you are interested in supporting this research project where we get the basics in place for the field or know someone who may be then please reach out to me so that we can screen the full library. If financial support isn’t possible, a simple thumbs up or comment is also a valuable way to show support and help us in spreading the word. Let’s see how much we can move the longevity needle together!